Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 255 results for radiotherapy

  1. Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over (TA1039)

    Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.

  2. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

  3. Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

    Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.

  4. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

  5. Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)

    This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.

  6. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued Reference number: GID-TA10443

  7. The MAGEC system for spinal lengthening in children with scoliosis (MT169)

    Discontinued Reference number: GID-MT544

  8. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.

  9. Electrochemotherapy for the treatment of malignant melanoma

    Discontinued Reference number: GID-IP1041

  10. Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)

    We have moved interventional procedures guidance 784 to become HealthTech guidance 714. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

  11. DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)

    Discontinued Reference number: GID-MT536

  12. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.

  13. Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer (IPG763)

    We have moved interventional procedures guidance 763 to become HealthTech guidance 681. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.  

  14. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (IPG752)

    We have moved interventional procedures guidance 752 to become HealthTech guidance 659. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.